Research progress of liver injury induced by crizotinib
10.3760/cma.j.cn114015-20221028-00998
- VernacularTitle:克唑替尼相关肝损伤研究进展
- Author:
Jun CHENG
1
;
Yixuan HAN
1
;
Long WANG
1
;
Lingna ZHU
1
Author Information
1. 安徽省蚌埠市第三人民医院药学部，蚌埠 233000
- Publication Type:Journal Article
- Keywords:
Enzyme inhibitors;
Liver;
Drug toxicity;
Chemical and drug induced liver injury;
Crizotinib;
Tyrosine kinase inhibitor
- From:
Adverse Drug Reactions Journal
2023;25(2):107-111
- CountryChina
- Language:Chinese
-
Abstract:
Crizotinib is a multi-target small molecule tyrosine kinase inhibitor, which can act on anaplastic lymphoma kinase (ALK), cellular-mesenchymal to epithelial transition factor and c-ros oncogene 1 (ROS1). It is mainly used in patients with ALK/ROS1-positive advanced non-small cell lung cancer. Liver injury is one of the most common adverse reactions of crizotinib. The typical symptom of crizotinib-induced liver injury is asymptomatic aminotransferase elevation, and fatal liver failure can occur in very few patients. The mechanism is mainly related to mitochondrial-mediated apoptosis, excessive autophagy, oxidative stress, and anaphylaxis. The risk factors involved are history of liver diseases, hepatitis B virus infection, combined use of immune checkpoint inhibitors or H 2-antagonist/proton pump inhibitor, gene polymorphisms of signal transducer and activator of transcription 1 and cytochrome P450. It is very important to assess liver function comprehensively before treatment, and strengthen the therapeutic drug monitoring during treatment. Measures such as temporary (reduce the dose when re-use) or permanent discontinuation should be taken when necessary.
